Riskpilot← Back to searchSign inGet full accessNovoinvent AB
ABActiveOrg 5567509848Rörsjögatan 2Tertiary education · NACE 8540Est. 20081 employees
Revenue 2024
SEK 1,6M
-21% vs 2023
EBITDA margin
48.5%
-34% vs 2023
Equity ratio
76.8%
Financial strength
Net profit 2024
SEK 707K
-7% vs 2023
| Revenue | SEK 1,6M | -21% |
| EBITDA | SEK 799K | -34% |
| Net profit | SEK 707K | -7% |
| Total assets | SEK 1,9M | +12% |
| Equity | SEK 1,4M | +17% |
| Employees | 1 | — |
Legal name
Novoinvent AB
Org number
5567509848
Legal form
Aktiebolag
NACE code
8540 · Tertiary education
Founded
30 januari 2008
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolagets verksamhet ska vara att bedriva forskning och utveckling av kirurgiska och medicintekniska instrument samt inplantat, utbildningsverksamhet samt förvalta lös och fast egendom och därmed förenlig verksamhet.
Address
Rörsjögatan 2
Email
henrik.thorlacius@med.lu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 597 | 1 163 | 1 317 | 2 081 | 1 646 |
| Staff expenses | — | — | −6 | −214 | −357 |
| EBITDA | 419 | 972 | 829 | 1 209 | 799 |
| Depreciation & amort. | −3 | −27 | −21 | −20 | −35 |
| EBIT | 416 | 945 | 807 | 1 188 | 764 |
| Net financials | −28 | 110 | −160 | −175 | 129 |
| Profit before tax | 398 | 1 056 | 648 | 1 013 | 894 |
| Tax | −87 | −221 | −143 | −254 | −187 |
| Net profit | 311 | 835 | 505 | 758 | 707 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 056 | 1 933 | 1 186 | 1 656 | 1 850 |
| Equity | 916 | 1 551 | 756 | 1 215 | 1 422 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 140 | 382 | 430 | 441 | 429 |
| Total debt | 140 | 382 | 430 | 441 | 429 |
EBITDA margin
48.5%
This company
15.8%
Market median
+207% vs market
20202024
Equity ratio
76.8%
This company
38.2%
Market median
+101% vs market
20202024
Return on equity
49.7%
This company
18.4%
Market median
+170% vs market
20202024
Net profit margin
43.0%
This company
8.1%
Market median
+431% vs market
20202024
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20202024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Novoinvent AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Tobias Thorlacius | Board of Directors | 0 companies |
| Johan Thorlacius | Deputy Board Member | 0 companies |